Structure Therapeutics (GPCR) vs Janux Therapeutics (JANX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Structure Therapeutics (GPCR) has outperformed Janux Therapeutics (JANX) over the past year, losing 9.8% versus a loss of 23.6%. Structure Therapeutics is the larger company by market cap ($1.83 billion vs $1.15 billion), about 1.6 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GPCR | JANX |
|---|---|---|
| Share price | $25.60 | $18.76 |
| Market cap | $1.83B | $1.15B |
| 1-day change | -0.29% | +1.38% |
| YTD return | -63.09% | +34.06% |
| 1-year return | -9.77% | -23.55% |
| 5-year return | — | -12.45% |
| EPS (TTM) | $-3.03 | $-1.64 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-141.20M | — |
| 52-week high | $94.90 | $35.34 |
| 52-week low | $25.09 | $12.12 |
| Distance from 52-week high | -73.03% | -46.93% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +313.28% | +93.23% |
| Average volume | 965.00K | 845.95K |
| Shares outstanding | 71.31M | 61.14M |
| Employees | 281 | 113 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- GPCR has outperformed JANX by 13.8 percentage points over the past year.
About Structure Therapeutics
GPCR stock →Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral small molecule therapeutics to treat various chronic diseases with unmet medical needs in the United States. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, which is in two phase 2 clinical trials for the treatment of obesity, overweight, and related conditions.
Health Care · Biotechnology: Pharmaceutical Preparations · 281 employees
About Janux Therapeutics
JANX stock →Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms technology to treat patients with cancer. The company's clinical candidates include JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor that is in Phase 1 clinical trial for the treatment of various solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, renal cell carcinoma, small cell lung cancer, pancreatic ductal adenocarcinoma, and triple-negative breast cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 113 employees
GPCR vs JANX FAQ
Which is bigger, Structure Therapeutics or Janux Therapeutics?
Structure Therapeutics (GPCR) is larger, with a market capitalization of $1.83B compared with $1.15B for Janux Therapeutics (JANX).
Which stock has performed better over the past year, GPCR or JANX?
GPCR returned -9.77% over the past 12 months, compared with -23.55% for JANX (price return, excluding dividends). Past performance does not predict future results.
Are Structure Therapeutics and Janux Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.